You are here:

rilpivirine (Edurant)

Advice

Following a full submission:
 
rilpivirine (Edurant®) is accepted for use within NHS Scotland.
 
Indication under review: rilpivirinein combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type1 (HIV‑1) infection in antiretroviral treatment‑naïve adult patients with a viral load ≤100,000 HIV‑1 RNA copies/mL.
 
The non-inferiority of rilpivirine over another non-nucleoside reverse transcriptase inhibitor (when given in combination with two nucleoside reverse transcriptase inhibitors) for virological response was demonstrated in two phase III, comparative, multi-centre studies in antiretroviral treatment-naïve patients.

Drug Details

Drug Name: rilpivirine (Edurant)
SMC Drug ID: 758/12
Manufacturer: Tibotec (Janssen-Cilag Ltd)
Indication: In combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in antiretroviral treatment naïve adult patients with a viral load ≤ 100,000 HIV 1 RNA copies/ml.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 13 February 2012

Back